In a cancer–sepsis model, PD-1 blockade did not confer a survival advantage and was associated with a loss of CXCR5+PD-1+ T cells and decreased CD28 expression, whereas blockade of another checkpoint receptor (2B4) significantly improved outcomes [89]. The gene discussed is CD28; the disease is Sepsis.